Line Malha

Dr. Line Malha

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2018 in Hypertension
Verified
Journal Article
Open access
PDF file
LMLine Malha
Line Malha
CSCristina P. Sison
Cristina P. Sison
GHGeraldine Helseth
Geraldine Helseth
JSJean E. Sealey
Jean E. Sealey
PAPhyllis August
Phyllis August
Pregnant women with chronic hypertension are at risk for increased blood pressure and superimposed preeclampsia (SPE) in late pregnancy. Alterations in the renin-aldosterone system are a feature of normal pregnancy; however, their role in chronic hypertension with and without SPE is less clear. We performed a prospective, longitudinal trial of 108 women with chronic hypertension and measured plasma renin activity (PRA), 24-hour urine sodium, urine potassium, and urine aldosterone (Ualdo) at 12, 20, 28, and 36 weeks and postpartum. SPE developed in 34% of pregnancies. PRA was lower in women who developed SPE at weeks 28 (5.99 versus 6.22 ng/mL per hour; P <0.001) and 36 (5.71 versus 7.74 ng/mL per hour; P =0.002). Ualdo was lower in women with SPE compared with those without SPE at 28 weeks (59.6 versus 81.3 μg/d; P =0.039). Mean arterial pressure was inversely related to both PRA ( r =−0.23; P <0.0001) and Ualdo ( r =−0.11; P =0.029). PRA and Ualdo were positively associated with each other ( r =0.5327; P <0.0001) after adjusting for urine potassium, urine sodium, serum potassium, and mean arterial pressure. PRA and Ualdo were lower in women of black race compared with other racial groups ( P <0.001). Our results demonstrate that in women with chronic hypertension PRA and Ualdo increase in early pregnancy and subsequently decrease in women who develop SPE. These findings are consistent with the hypothesis that sodium retention may contribute to the elevation in blood pressure in SPE.

Verified
Journal Article
Open access
PDF file
Vahid BazojooVahid Bazojoo
Vahid Bazojoo
VDVahid Davoudi
Vahid Davoudi
JBJon Blumenfeld
Jon Blumenfeld
CZChenglin Zhu
Chenglin Zhu
LMLine Malha
Line Malha
Martin R PrinceMartin R Prince
Martin R Prince
Background/Objectives: Polycystic liver disease (PLD) is the most common extrarenal manifestation of autosomal dominant polycystic kidney disease (ADPKD). PLD is more prevalent in women, and women have larger liver cysts, possibly due to estrogen-related mechanisms. Maternal estrogen levels normally increase during pregnancy. Thus, we investigated the pregnancy-associated increase in liver volume, liver cyst volume, total kidney volume (TKV), and kidney cyst growth rates in ADPKD patients. Methods: Kidney, liver, and cyst volumes were measured in 16 ADPKD patients by magnetic resonance imaging (MRI) at multiple timepoints before and after pregnancy. The log-transformed TKV, liver volume, and cyst volume growth rates during a period with pregnancy were compared to a period without pregnancy. Results: In ADPKD patients, a higher annualized liver cyst growth rate was observed during a period with pregnancy compared to a period without pregnancy (34 ± 16%/yr vs. 23 ± 17%/yr; p-value = 0.005). Liver volume growth was also higher during a period with pregnancy, 6 [2, 7]%/yr vs. 0.3 [−0.4, 2]%/yr (p-value = 0.04). In addition, the mean kidney cyst growth rate was higher (12 ± 11%/yr vs. 4 ± 9%/yr; p-value = 0.05), and there was a trend toward a pregnancy-associated increase in the TKV growth rate (6 [4, 8]%/yr vs. 3 [0.8, 5]%/yr, (p-value = 0.14) during a period with pregnancy. Conclusions: In patients with ADPKD, the liver volume and cyst volume growth rates increased during pregnancy. This supports the hypothesis that the estrogen-mediated stimulation of liver cyst growth may contribute to the severe polycystic liver disease that is more prevalent in women than men with ADPKD. Further studies with larger populations are needed to explore the mechanisms and long-term implications of these findings.

11 February 2019 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
LMLine Malha
Line Malha
HFHasan Fattah
Hasan Fattah
FMFrank Modersitzki
Frank Modersitzki
DGDavid S. Goldfarb
David S. Goldfarb
Volume overload and depletion both lead to high morbidity and mortality. Achieving euvolemia is a challenge in patients with end stage kidney disease on hemodialysis (HD). Blood volume analysis (BVA) uses radiolabeled albumin to determine intravascular blood volume (BV). The measured BV is compared to an ideal BV (validated in healthy controls). We hypothesized that BVA could be used in HD to evaluate the adequacy of the current clinically prescribed “estimated dry weight” (EDW) and to titrate EDW in order to improve overall volume status. We were also interested in the reproducibility of BVA results in end stage kidney disease. Twelve adults on chronic HD were recruited; 10 completed the study. BVA (Daxor, New York, NY, USA) was used to measure BV at baseline. EDW was kept the same if the patient was deemed to be euvolemic by BVA otherwise, the prescribed EDW was changed with the aim that measured BV would match ideal BV. A second BVA measurement was done 1–3 months later in order to measure BV again. Based on BVA, 6/10 patients were euvolemic at baseline and 5/10 were euvolemic at the second measurement. When comparing patients who had their prescribed EDW changed after the initial BVA to those who did not, both groups had similar differences between measured and ideal BV (P = 0.75). BV values were unchanged at the second measurement (P = 0.34) and there was no linear correlation between BV change and weight change (r2 = 0.08). This pilot study is the first longitudinal measurement of BVA in HD patients. It revealed that changing weight did not proportionally change intravascular BV. BV remained stable for 1–3 months. BVA may not be helpful in clinically stable HD patients but studies on patients with hemodynamic instability and uncertain volume status are needed. ClinicalTrials.gov (NCT02717533), first registered February 4, 2015.

1 September 2017 in Mayo Clinic Proceedings
Verified
Journal Article
Closed access
LMLine Malha
Line Malha
PAPhyllis August
Phyllis August

1 September 2025 in Hypertension
Verified
Journal Article
Closed access
LMLine Malha
Line Malha
PAPhyllis August
Phyllis August

3 August 2026 in Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
LMLine Malha
Line Malha
PAPhyllis August
Phyllis August
Hypertensive disorders of pregnancy affect approximately 9% of pregnancies in the United States and are a leading cause of maternal morbidity and mortality. For nephrologists, these conditions sit at a critical intersection: CKD is among the strongest risk factors of preeclampsia, and pregnancy itself can unmask previously unrecognized kidney disease. The physiologic demands of gestation stress renal and vascular reserve in ways that make the pregnant and immediately postpartum patient particularly vulnerable. Preeclampsia, driven by placental release of antiangiogenic factors and widespread maternal endothelial dysfunction, produces acute cardiorenal injury that does not entirely resolve with delivery. Postpartum hypertension peaks between days 3 and 6 after delivery and is under-recognized, yet this period carries the greatest risk of preventable maternal death, with cardiovascular causes accounting for more than one third of pregnancy-related deaths. Beyond the acute phase, women with hypertensive pregnancies face accelerated trajectories toward chronic hypertension, CKD, and overall cardiometabolic risks that compound with each affected pregnancy. The postpartum visit represents a critical and underutilized opportunity to identify women who warrant nephrology evaluation, initiate renoprotective therapy, and interrupt a long-term cardiorenal disease course. Nephrologists are well positioned to recognize cardiorenal sequelae of hypertensive pregnancy and ensure that the postpartum period is not a missed opportunity for intervention. This review addresses the diagnosis, pathophysiology, and management of hypertensive disorders across the full peripartum continuum, with particular attention to the role of nephrologists in recognizing kidney disease that pregnancy has brought to light and in ensuring that delivery is not treated as a clinical end point.